SCLEROSIS, SYSTEMIC
Clinical trials for SCLEROSIS, SYSTEMIC explained in plain language.
Never miss a new study
Get alerted when new SCLEROSIS, SYSTEMIC trials appear
Sign up with your email to follow new studies for SCLEROSIS, SYSTEMIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug HZN-825 tested for rare scleroderma lung and skin damage
Disease control TerminatedThis trial tested an experimental drug called HZN-825 in about 300 people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes skin thickening and can damage the lungs. Participants took either a low dose, a high dose, or a placebo daily for 52 weeks. …
Matched conditions: SCLEROSIS, SYSTEMIC
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental drug HZN-825 tested for rare autoimmune lung complication
Disease control TerminatedThis trial tested the drug HZN-825 in 174 people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that can scar the lungs. Participants took the drug twice daily for 52 weeks to see if it helped maintain lung function and to check for side effects. The study w…
Matched conditions: SCLEROSIS, SYSTEMIC
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC